Skip to content
Government Federal, Medical Health Aged Care

Consumer Health Forum welcomes PBS price cut for essential medicines

Consumers Health Forum of Australia 2 mins read

The Consumers Health Forum of Australia (CHF) has welcomed today’s announcement, with bipartisan support, to reduce the maximum co-payment under the Pharmaceutical Benefits Scheme (PBS) to $25 from January 2026.

CHF CEO Dr Elizabeth Deveny said this measure, which CHF has long called for, is a step towards alleviating cost pressures, with the price cut bringing meaningful relief to millions.

“This is a major win for Australian health consumers and something CHF has consistently advocated for,” Dr Deveny said. “Every dollar matters when people are choosing between food, bills and essential medication, and this is a significant win for health consumers struggling with the rising cost of living.

“What we have heard from consumers ever since the rise in cost-of-living is that they have had to choose between paying for essentials or filling their prescriptions. Today’s announcement will ease the burden for millions.

“Helping Australians better afford their medicine provides people with dignity and health provides better health outcomes including preventing avoidable hospital admissions. It benefits the entire system.”

Dr Deveny also said there was more work to do to improve the overall PBS, including automating its safety net scheme. 

“Right now, we know many Australians miss out on savings they are eligible for under the PBS because of outdated systems. By automating this scheme, like Medicare, the onus won’t be on consumers and pharmacists to help make medicines more affordable,” Dr Deveny said. 

Dr Deveny warned many Australians still don’t fully understand how medicine pricing works under the PBS.

“The PBS is complex and most people don’t realise there are multiple payment tiers based on personal circumstance,” Dr Deveny said.

Under the PBS, medication costs vary based on whether a person holds a concession card, has reached the PBS Safety Net threshold, or is purchasing a medicine priced below the standard co-payment. 

Confusion between these can mean people miss out on discounts they are entitled to. 

“Too many consumers don’t know what to expect when they get to the pharmacy counter, or how to make the most of PBS benefits,” Dr Deveny said.

“Without better public information and modernised systems, people will continue to fall through the cracks. Australians deserve to know what’s available to them.”


Contact details:

Lauren Ferri: 0422 581 506

Kathleen Ferguson: 0421 522 080

More from this category

  • Medical Health Aged Care
  • 26/04/2025
  • 08:04
Monash University

The power of pets in reducing loneliness and social isolation for at-risk groups

A new pilot program funded by the National Centre for Healthy Ageing (NCHA), a partnership between Monash University and Peninsula Health, is the first to use a shared interest in pets to help build connections between young and older adults to reduce loneliness and social isolation. Social isolation and loneliness stem from a reduced sense of belonging, due to a lack of social connections, and can lead to detrimental effects on physical health and cognitive decline. These experiences have been exacerbated due to the COVID-19 pandemic. Two of the most impacted groups in relation to social isolation and loneliness are…

  • Medical Health Aged Care
  • 25/04/2025
  • 18:11
Elixir Medical Corporation

Elixir Medical Announces First Use of LithiX Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in Asia Pacific at Cardiac Vascular Sentral Kuala Lumpur (CVSKL), Malaysia

First cases completed by Dr. Tamil Selvan Muthusamy, MD, and Dr. Rosli Mohd Ali, MD, and transmitted live at TCTAP Congress in Seoul, Korea.Novel IVL technology designed to deliver calcium fragmentation for treatment of moderate to severely calcified coronary artery lesions without requiring an external energy source.MILPITAS, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced the first clinical use of its LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in the Asia Pacific region, marking a significant milestone in the device's global introduction. The procedures were successfully performed…

  • Medical Health Aged Care
  • 25/04/2025
  • 09:59
Monash University

Repurposed diabetes drug can reduce pain for those with knee arthritis and overweight or obesity: study

A common diabetes drug can reduce the pain of people with knee osteoarthritis and overweight or obesity, possibly delaying the need for knee replacements, Monash University-led research has found. Metformin, which is commonly prescribed to treat type 2 diabetes, reduced knee arthritis pain over six months in a clinical trial published in JAMA. The randomised clinical trial looked at whether metformin, compared to a placebo, reduced knee pain in patients withsymptomatic knee osteoarthritis (knee OA) andoverweight or obesity. The research was performed entirely as a community-based study using telehealth. Some of the 107 participants with pain from knee osteoarthritis (73…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.